Prognostic impact of lung recurrence in patients with biliary tract cancer.
Biliary tract carcinoma
Lung
Recurrence
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
31 Jul 2023
31 Jul 2023
Historique:
received:
14
03
2023
accepted:
11
07
2023
medline:
23
10
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
This study aimed to evaluate the prognostic impact of the initial recurrence site following resection for biliary tract carcinoma (BTC), focusing on lung recurrence. The clinical data of patients with recurrent BTC who underwent curative intent surgery between March 2009 and December 2021 were retrospectively analyzed. The prognosis of patients with recurrent BTC was investigated in each recurrence site. Eligible patients were classified into two groups according to lung or non-lung recurrence. Clinicopathological factors, survival after recurrence, and overall survival were compared between the two groups. Independent factors associated with survival after recurrence were investigated using multivariate analysis. Of 119 patients, the initial recurrence site was local in 26 (21.8%) patients, liver in 19 (16.8%), peritoneum in 14 (11.8%), lymph node in 12 (10.1%), lung in 11 (9.2%), multiple organs in 32 (26.9%), and others in 5 (4.2%). The survival period after recurrence in patients with lung recurrence was significantly longer than those in patients with other six recurrence patterns. The median survival after recurrence was 34.3 and 9.3 months in lung recurrence and non-lung recurrence groups, respectively (p < 0.0001); that after initial surgery was 50.8 and 26.4 months, respectively (p = 0.0383). Multivariate analysis revealed that lung recurrence and normal albumin level at recurrence were independently associated with survival after recurrence (Hazard Ratio (HR), 0.291; p = 0.0128; HR, 0.476; p = 0.00126, respectively). Survival period after recurrence was significantly longer in patients with lung recurrence.
Identifiants
pubmed: 37522989
doi: 10.1007/s00423-023-03015-y
pii: 10.1007/s00423-023-03015-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
290Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517
doi: 10.1097/00000658-200110000-00010
pubmed: 11573044
pmcid: 1422074
de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368–1378
doi: 10.1056/NEJM199910283411807
pubmed: 10536130
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15:95–111
doi: 10.1038/nrclinonc.2017.157
pubmed: 28994423
Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37:806–813
doi: 10.1016/S0168-8278(02)00297-0
pubmed: 12445422
Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 48:816–820
doi: 10.1136/gut.48.6.816
pubmed: 11358902
pmcid: 1728314
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N et al (2013) Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg 17:1429–1439
doi: 10.1007/s11605-013-2251-0
pubmed: 23797881
Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Nomura T et al (2010) Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer 116:400–405
doi: 10.1002/cncr.24766
pubmed: 19950133
Blom D, Schwartz SI (2001) Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg 136:209–215
doi: 10.1001/archsurg.136.2.209
pubmed: 11177143
Kamposioras K, Anthoney A, Fernández Moro C, Cairns A, Smith AM, Liaskos C et al (2014) Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg 101:89–99
doi: 10.1002/bjs.9367
pubmed: 24375301
Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG et al (2005) Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 241:77–84
doi: 10.1097/01.sla.0000150166.94732.88
pubmed: 15621994
pmcid: 1356849
Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J et al (2005) Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 137:396–402
doi: 10.1016/j.surg.2004.10.008
pubmed: 15800484
Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. ABC-02 Trial Investigators. N Engl J Med 362:1273–1281
doi: 10.1056/NEJMoa0908721
pubmed: 20375404
Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950–1958
doi: 10.1093/annonc/mdz402
pubmed: 31566666
Otsuka H, Uemura K, Kondo N, Sumiyoshi T, Nakagawa N, Okada K et al (2020) Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Pancreatology 20:1472–1478
doi: 10.1016/j.pan.2020.08.019
pubmed: 32900632
Kurahara H, Maemura K, Mataki Y, Tanoue K, Iino S, Kawasaki Y et al (2020) Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Pancreatology 20:89–94
doi: 10.1016/j.pan.2019.11.015
pubmed: 31787525
Homma Y, Endo I, Matsuyama R, Sho M, Mizuno S, Seyama Y et al (2022) Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis. J Hepatobiliary Pancreat Sci 29:552–561
doi: 10.1002/jhbp.1127
pubmed: 35179827
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T et al (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401:195–203
doi: 10.1016/S0140-6736(22)02038-4
pubmed: 36681415
Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y et al (2013) Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 258:129–140
doi: 10.1097/SLA.0b013e3182708b57
pubmed: 23059502
Orimo T, Kamiyama T, Mitsuhashi T, Kamachi H, Yokoo H, Wakayama K et al (2018) Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma. J Gastroenterol 53:1206–1215
doi: 10.1007/s00535-018-1469-8
pubmed: 29721628
Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakagawa N et al (2008) No mortality after 150 consecutive pancreatoduodenctomies with duct-to-mucosa pancreaticogastrostomy. J Surg Oncol 97:205–209
doi: 10.1002/jso.20903
pubmed: 18050288
Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H et al (2009) Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250:950–956
doi: 10.1097/SLA.0b013e3181b0fc8b
pubmed: 19953713
Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA et al (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154–1162
doi: 10.1097/SLA.0000000000002734
pubmed: 31082915
Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T et al (2015) Surgery for recurrent biliary tract cancer: a single-center experience with 74 consecutive resections. Ann Surg 262:121–129
doi: 10.1097/SLA.0000000000000827
pubmed: 25405563
Yamada M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T et al (2017) Pulmonary metastasis after resection of cholangiocarcinoma: incidence, resectability, and survival. World J Surg 41:1550–1557
doi: 10.1007/s00268-017-3877-y
pubmed: 28105527
Oshikiri T, Morita T, Fujita M, Miyasaka Y, Senmaru N, Yamada H, Kaji N, Kondo S (2006) Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. Cancer Lett 237:115–122
doi: 10.1016/j.canlet.2005.05.050
pubmed: 16039043
Goto T, Urakami H, Akanabe K, Maeshima A, Kato R (2011) Solitary pulmonary metastasis from carcinoma of the papilla of vater. Ann Thorac Cardiovasc Surg 17:404–407
doi: 10.5761/atcs.cr.10.01611
pubmed: 21881331
Pih GY, Kim DK, Park KM, Chang HM (2017) Bilateral lung metastasectomy in carcinoma of the ampulla of Vater. Thorac Cancer 8:124–127
doi: 10.1111/1759-7714.12418
pubmed: 28168842
pmcid: 5334294
Sakamoto T, Honjo S, Morimoto M, Amisaki M, Arai Y, Tokuyasu N et al (2018) Successful resection of a slow-growing synchronous pulmonary metastasis from distal cholangiocarcinoma resected 3.5 years after initial surgery: a case report. J Med Case Rep 12:136
doi: 10.1186/s13256-018-1671-6
pubmed: 29784024
pmcid: 5963088
Sakata J, Nomura T, Aono T, Kitami C, Yokoyama N, Minagawa M et al (2021) Oncological outcomes of surgery for recurrent biliary tract cancer: who are the best candidates? HPB 23:1371–1382
doi: 10.1016/j.hpb.2021.01.007
pubmed: 33558069